Short answer
LB PHARMACEUTICALS INC (LBRX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers quarterly financial results for the period ended September 30, 2026.
LB PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers quarterly financial results for the period ended September 30, 2026
- Exhibit 99.1 contains the detailed results investors need to assess performance and financial condition
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 R&D spending rose to $51.5M from $2.4M, reflecting accelerated Phase 3 and Phase 2 development
- Net loss widened to $59.1M from $3.6M, increasing clinical-stage cash burn
- Cash, equivalents and short-term investments reached $403.8M, projected to fund operations beyond Q2 2029
- $150.0M private placement generated approximately $140.9M net proceeds for new LB-102 indications and corporate purposes
- NOVA-2 schizophrenia Phase 3 topline data remains expected in 1H 2027, the key near-term clinical catalyst
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LB PHARMACEUTICALS INC 8-K filings
Get the next LBRX 8-K as it lands
Follow LBRX for push alerts, or ask the research agent what this filing means.